The study of efficacy and safety of palonosetron for high-risk chemotherapy induced nausea and vomiting in malignant lymphoma.
Phase 2
- Conditions
- Malignant lymphoma
- Registration Number
- JPRN-UMIN000008966
- Lead Sponsor
- Shimane University Hospital,cancer center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patient has severe complication require treatment. 2)Patient has more than CTCAE grade1 nausea and vomiting before chemotherapy. 3)Patient has hypersensitivity of Palonosetron or the other 5-HT3 antagonist. 4)Pregnant or nursing women. Patient refuses to contraception. 5)Patient is deemed inappropriate by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete response during chemotherapy
- Secondary Outcome Measures
Name Time Method